A Novel Imaging Grading Biomarker for Predicting Hearing Loss in Acoustic Neuromas.,Clinical Neuroradiology

当前位置： X-MOL 学术 › Clin. Neuroradiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Novel Imaging Grading Biomarker for Predicting Hearing Loss in Acoustic Neuromas.
Clinical Neuroradiology ( IF 2.8 ) Pub Date : 2020-07-27 , DOI: 10.1007/s00062-020-00938-7
Wenjianlong Zhou _{1,

2} , Yangyang Wang ₁ , Shunchang Ma _{1,

3,

4} , Linhao Yuan ₁ , Xi Wang ₁ , Jiayi Peng ₁ , Dainan Zhang ₁ , Xiudong Guan ₁ , Deling Li ₁ , Guijun Jia ₁ , Wang Jia _{1,

3,

4}

Affiliation

Purpose

The aim of this study was to investigate an imaging biomarker based on contrast enhanced T1-weighted and T2-weighted magnetic resonance imaging (MRI) to determine the hearing loss related to acoustic neuromas (AN).

Methods

In this retrospective study, 441 acoustic neuromas treated with microsurgery were included. The diagnostic and follow-up MRI and audiometry of these patients were compared.

Results

We discovered a new MRI grading biomarker based on the percentage of tumor filling the inner auditory canal (TFIAC classification). The area under the receiver operating characteristics (AUROC) curve was highest for TFIAC (0.675), followed by period of observation (0.615) and tumor size (0.6) (P < 0.001). The percentage of patients in TFIAC grade III (90.1%) experiencing hypoacusis prior to microsurgery was significantly higher than that in TFIAC grade I (72.7%, P = 0.037) and TFIAC grade IV patients had a higher rate of non-serviceable hearing compared to TFIAC grade III patients (P < 0.001). During the follow-up, TFIAC grade IV patients experienced a significantly higher rate of non-serviceable hearing than TFIAC grade III patients in all ANs (P < 0.001) and in serviceable hearing acoustic neuroma cases prior to surgery (TFIAC grade IV 55.4%, TFIAC grade III 69.0%, P = 0.045). The TFIAC grade IV patients experienced a significantly higher rate of facial nerve dysfunction than TFIAC grade III patients after surgery (grade IV 48.0%, grade III 26.1%, P < 0.001).

Conclusion

The TFIAC classification serves as a potential imaging biomarker for preoperative and postoperative hearing prediction in ANs, which may aid neurosurgeons in predicting hearing loss and selecting optimal surgical strategies.

中文翻译：

一种用于预测听神经瘤听力损失的新型成像分级生物标志物。

目的

本研究的目的是研究基于对比增强 T1 加权和 T2 加权磁共振成像 (MRI) 的成像生物标志物，以确定与听神经瘤 (AN) 相关的听力损失。

方法

在这项回顾性研究中，包括 441 名接受显微手术治疗的听神经瘤。对这些患者的诊断和随访 MRI 和听力测量进行了比较。

结果

我们发现了一种新的 MRI 分级生物标志物，该生物标志物基于肿瘤填充内耳道的百分比（TFIAC 分类）。TFIAC 的受试者操作特征 (AUROC) 曲线下面积最高 (0.675)，其次是观察期 (0.615) 和肿瘤大小 (0.6) ( P  < 0.001)。显微手术前 TFIAC III 级患者 (90.1%) 出现听力减退的百分比显着高于 TFIAC I 级患者(72.7%, P = 0.037) 且 TFIAC IV 级患者的非可用听力发生率高于TFIAC III 级患者 ( P  < 0.001)。在随访期间，在所有 AN 中，TFIAC IV 级患者的非可用听力发生率显着高于 TFIAC III 级患者。P  < 0.001）和手术前听力正常的听神经瘤病例（TFIAC IV 级 55.4%，TFIAC III 级 69.0%，P  = 0.045）。TFIAC IV 级患者术后面神经功能障碍发生率明显高于 TFIAC III 级患者（IV 级 48.0%，III 级 26.1%，P  < 0.001）。